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Ligand trap of the activin receptor type IIA inhibits osteoclast 
stimulation of bone remodeling in diabetic mice with chronic 
kidney disease
Toshifumi Sugatani1, Olga A. Agapova1, Yifu Fang1, Alycia G. Berman2, Joseph M. 
Wallace2, Hartmut H. Malluche3, Marie-Claude Faugere3, William Smith4, Victoria Sung5, 
and Keith A. Hruska1
1Department of Pediatrics and Medicine, Renal Division, Washington University, St. Louis, 
Missouri, USA
2Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, 
Indianapolis, Indiana, USA
3Division of Nephrology, Bone and Mineral Metabolism, Department of Medicine, University of 
Kentucky, Lexington, Kentucky, USA
4Early Clinical Development, Celgene Corp., Basking Ridge, New Jersey, USA
5Translational Medicine, Celgene Corp., San Francisco, California, USA
Abstract
Dysregulation of skeletal remodeling is a component of renal osteodystrophy. Previously, we 
showed that activin receptor signaling is differentially affected in various tissues in chronic kidney 
disease (CKD). We tested whether a ligand trap for the activin receptor type 2A (RAP-011) is an 
effective treatment of the osteodystrophy of the CKD-mineral bone disorder. With a 70% 
reduction in the glomerular filtration rate, CKD was induced at 14 weeks of age in the ldlr−/− high 
fat-fed mouse model of atherosclerotic vascular calcification and diabetes. Twenty mice with 
CKD, hyperphosphatemia, hyperparathyroidism, and elevated activin A were treated with 
RAP-011, wherease 19 mice were given vehicle twice weekly from week 22 until the mice were 
killed at 28 weeks of age. The animals were then evaluated by skeletal histomorphometry, micro-
computed tomography, mechanical strength testing, and ex vivo bone cell culture. Results in the 
CKD groups were compared with those of the 16 sham-operated ldlr−/− high fat-fed mice. Sham-
operated mice had low-turnover osteodystrophy and skeletal frailty. CKD stimulated bone 
remodeling with significant increases in osteoclast and osteoblast numbers and bone resorption. 
Compared with mice with CKD and sham-operated mice, RAP-011 treatment eliminated the 
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CKD-induced increase in these histomorphometric parameters and increased trabecular bone 
fraction. RAP-011 significantly increased cortical bone area and thickness. Activin A-enhanced 
osteoclastogenesis was mediated through p-Smad2 association with c-fos and activation of nuclear 
factor of activated T cells c1 (NFATc1). Thus, an ActRIIA ligand trap reversed CKD-stimulated 
bone remodeling, likely through inhibition of activin-A induced osteoclastogenesis.
Keywords
activin A; activin receptor type IIA; chronic kidney disease; renal osteodystrophy; signaling
Renal osteodystrophy is a component of the chronic kidney disease-mineral bone disorder 
(CKD-MBD) syndrome. It causes a high incidence of skeletal fractures and contributes to 
the high mortality rates associated with kidney diseases.1 Following the naming of the CKD-
MBD syndrome,2 it became apparent that the syndrome had an earlier onset in the course of 
kidney disease than the hyperparathyroidism and calcitriol deficiency that had previously 
been linked to renal osteodystrophy.3,4 Characterization of CKD-MBD in early CKD 
demonstrated onset in stage 2 CKD both clinically and in translational models.4–8 In early 
CKD, the CKD-MBD was characterized by arterial vascular cell dedifferentiation/
calcification, loss of klotho, increased fibroblast growth factor 23 (FGF-23) secretion, and an 
osteodystrophy.7 Progress in understanding the causes of the CKD-MBD has been 
made,6,9–11 but the nature of early osteodystrophy and its causes are mostly unknown.
We have shown that CKD directly produces an osteodys-trophy.12 In C57BL/6J mice 
subjected to renal ablation, with phosphate, calcium, parathyroid hormone (PTH), and 
calcitriol at normal levels, a low-turnover osteodystrophy, the adynamic bond disorder, was 
produced.12 We next showed that renal injury produced circulating Wnt inhibitors and 
inhibited the bone formation rate. Renal injury stimulated several kidney Wnts (portmanteau 
of Wingless and Integrated) and Wnt inhibitors among the nephrogenic factors reactivated in 
renal repair.13,14 The Wnt inhibitors are circulating factors, and the family includes the 
Dickkopfs (Dkk), whose levels are increased in the circulation in CKD.9,14 Neutralization of 
a key Wnt inhibitor elevated in the circulation in CKD, Dkk1, was efficacious in treating the 
CKD-MBD,9 by inhibiting CKD-induced vascular dedifferentiation, vascular calcification, 
and increasing bone formation in the renal osteodys-trophy.9 That kidney-disease produced 
Wnt inhibitors are a factor in the osteodystrophy of early CKD is in agreement with clinical 
and translational studies from de Oliveira et al.,10 Sabbagh et al.,11 and Moe et al.15
We have also shown that changes in transforming growth factor-β (TGF-β) superfamily 
function are involved in the pathogenesis of the CKD-MBD and that they may be upstream 
of Wnt activation in CKD.12,16 Bone morphogenetic protein 7 (BMP-7) deficiency during 
development causes renal hypoplasia/dysplasia and skeletal patterning abnormalities,17 and 
it is lost in kidney disease.18,19 In a diabetic CKD model, BMP-7 administration prevented 
vascular cell dedifferentiation and calcification20 and stimulated bone formation in low-
turnover osteodystrophy.12 When BMP-7 was administered to a model of high-turnover 
renal osteodystrophy, it further increased bone formation rates and increased bone mass.21 
BMP-7, like all TGF-β family ligands, binds to type 2 receptors, which associate and 
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activate type 1 receptors, initiating signal transduction. Besides TGF-β receptor II and bone 
morphogenetic protein type 2 receptor, the activin receptor type 2A (ActRIIA) and activin 
receptor type 2B are the most important type 2 receptors of the superfamily, and ActRIIA is 
a BMP-7 receptor.22 Activin A inhibits BMP-7 signaling by binding ActRIIA.23 We recently 
reported the effects of a ligand trap for ActRIIA on CKD-stimulated renal fibrosis and aortic 
calcification.16 We found that CKD decreased aortic vascular smooth muscle cell ActRIIA 
levels, and ActRIIA signaling was decreased by CKD in our diabetic model.16 The ActRIIA 
ligand trap increased aortic ActRIIA signaling measured by Smad activation, blocked CKD-
stimulated vascular smooth muscle osteoblastic transition, and decreased atherosclerotic 
vascular calcification. In the kidney, we found that the ligand trap increased renal αklotho 
expression. Furthermore, in the kidney, ActRIIA levels were not changed by CKD, and the 
ligand trap decreased renal ActRIIA signaling. The ligand trap also decreased renal Wnt 
activation and decreased circulating Dkk1. Renal fibrosis and proteinuria were decreased by 
the ActRIIA ligand trap. Thus, key components of the CKD-MBD, vascular calcification 
and decreased klotho, were affected by the ligand trap. Here we report the effects of the 
ligand trap on the skeleton, PTH, and FGF-23 components of the CKD-MBD in the mice 
from the Agapova et al.16 study.
The model of CKD that we studied involves the most common cause of CKD, type 2 
diabetes, which is associated with an osteodystrophy independent of CKD, and is 
characterized by low bone turnover and skeletal frailty despite normal bone density by dual-
energy x-ray absorptiome-try.24,25 This characterization is similar to that of low-turnover 
renal osteodystrophy and prompts us to question how early CKD affects the osteodystrophy 
of type 2 diabetes. Our murine model of type 2 diabetes, atherosclerosis, and atherosclerotic 
calcification in ldlr−/− high fat-fed mice harbors a low-turnover baseline osteodystrophy,7,9 
and circulating Wnt inhibitors contribute to the effects of CKD.9 Because the ActRIIA 
ligand trap decreased circulating Dkk1, we focused on factors of the TGF-β family produced 
by kidney disease that circulate and may perturb normal physiologic systemic processes. 
Here we demonstrate in our model that CKD stimulated bone remodeling and osteoclast 
stimulation is inhibited by the ActRIIA ligand trap.
RESULTS
To analyze the role of ActRIIA in the CKD-MBD, we utilized a ligand trap consisting of the 
murine extracellular domain of ActRIIA fused to a murine IgG-Fc fragment. The 
experimental design of the ligand trap experiments in the high fat–fed ldlr−/− mouse with 
ablative CKD is shown in Supplementary Figure S1.
Baseline osteodystrophy harbored by sham-operated Idlr−/− mice
We first characterized the state of the skeleton in the baseline control sham-operated mice 
because high-fat feeding26 and the high fat-fed ldlr−/− mouse27,28 have been shown to 
produce a low-turnover osteodystrophy. The high fat–fed ldlr−/− mouse has insulin 
resistance that progresses to type 2 diabetes by 28 weeks of age.20,29 The mice (sham, the 
sham-operated group in these studies) harbor an osteodystrophy characterized 
histomorphometrically by relatively maintained osteoclast numbers/surfaces compared with 
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wild-type (WT) C57B6J mice (Figure 1). However, osteoblast numbers/surfaces, bone 
formation rates, and osteoblast efficiency were significantly decreased in sham mice (Figure 
2), and osteoid volume and surfaces were significantly decreased in sham mice as was the 
mineral apposition rate, but only a trend toward decreased mineralization lag time was found 
(Figure 3). The decrease in osteoblast number in the sham mice is in agreement with our 
recent studies,9 but it is more pronounced than in our earlier studies.30,31 The basis for this 
phenotypic change in the sham mice is not known, but was associated with the change to 
blinded histomorphometry performed in Dr. Malluche’s laboratory. Although trabecular 
bone architecture was not significantly altered in the sham mice (Figure 4), total area and 
cortical bone area were decreased in the femoral midshaft (Figure 5). The effects of diabetes 
and the lipodystrophy on the mechanical properties of long bones assessed by 4-point 
bending of femora demonstrated a profound decrease in fracture resistance. Structural 
differences (decreases in elastic, postyield and total displacement and work) were driven by 
tissue effects. In the tissue, there were significant decreases in strength (yield and ultimate 
stress) (Supplementary Figure S2) and strain that resulted in decreased resilience and 
toughness (Supplementary Figure S2) in the femora of sham mice compared with those of 
WT mice.
Effects of CKD on the osteodystrophy harbored by sham-operated ldlr−/− mice
In addition to the background low-turnover osteodystrophy of the sham high fat-fed ldlr−/− 
mice, we induced kidney injury and nephrectomy producing repair/hypertrophy of the 
remnant kidney and CKD. In previous studies, when we induced milder CKD with reduction 
in glomerular filtration rate (GFR) of only 30% to 40%, the low-turnover osteodystrophy of 
the sham mice (cited previously) persisted despite CKD, and PTH levels were not elevated.9 
In the studies reported here, with the addition of CKD and the reduction in GFR of 70%, the 
low-turnover state of the high fat-fed ldlr−/− skeleton was overcome by stimulation of bone 
remodeling (Figures 1–3).
As shown in Figure 1, the CKD mice treated with vehicle (CKD V) had significant increases 
in osteoclast numbers and surfaces and in eroded surfaces. The CKD mice had a 
significantly increased osteoblast number and surface compared with sham mice but not to 
the full correction levels of WT mice (Figure 2). The bone formation rate (BFR) per bone 
surface, although trending greater than that of the sham, remained depressed compared with 
WT mice. There was a decrease in osteoblast efficiency (BFR/osteoblast number) (Figure 2). 
Mineralizing surfaces were increased by CKD (Table 1). Mineralization lag time and 
mineral apposition rate were not affected by CKD (Figure 3). The histomorphometric 
parameters of trabecular morphology were confirmed by micro computed tomography (CT) 
analysis (Figure 4). CKD-induced a trend toward increased bone volume (bone volume/total 
volume) and increased bone mineral density in the trabeculae. In addition, CKD increased 
total area and decreased cortical bone area fraction in the femora (Figure 5). The change in 
bone turnover produced by CKD resulted in increases in deformability and energy 
dissipation at both the structural and tissue levels, indicative of an increase in resistance to 
fracture compared with the diabetic sham mice (Figure 6).
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Effects of the ActRIIA ligand trap on trabecular bone histomorphometry, micro CT, and 
mechanical strength testing of bones from CKD RAP-011 -treated mice
Treatment with the ActRIIA ligand trap, RAP-011 (CKD R), decreased osteoclast number 
and osteoclast surfaces and eroded surfaces (Figure 1), as well as osteoblast numbers and 
surfaces (Figure 2) compared with vehicle-treated CKD mice. Overall BFRs were decreased 
by RAP-011, but bone formation rate per osteoblast was increased by RAP-011 treatment 
(Figure 2). RAP-011 decreased osteoid volume and surfaces (Figure 3), but did not affect 
mineralization lag time. The histomorphometric effects of RAP-011 treatment were 
confirmed by micro CT, showing that RAP-011 increased bone volume and trabeculae 
number while decreasing trabecular separation (Figure 4). In the femoral midshaft, RAP-011 
increased cortical bone area and cortical thickness compared with femora from CKD V 
(Figure 5). The trend toward increased deformability and energy dissipation in the fracture-
resistance studies produced by RAP-011 treatment were similar to the CKD V mice but did 
not achieve significance (Figure 6).
Effects of the ActRIIA ligand trap on PTH levels, serum chemistries, and FGF-23 levels
The effects of RAP-011 on osteoclast and osteoblast surfaces and BFRs are surprising, 
especially because the ActRIIA ligand trap had no effects on plasma PTH levels (Figure 7), 
which are the supposed means of regulating osteoclast and osteoblast numbers and 
stimulating high-turnover osteodystrophy in CKD.32 This means that an ActRIIA ligand 
participated in the stimulation of bone remodeling, probably through the direct effects of 
osteoclast stimulation. Treatment with RAP-011 had no effect on the serum phosphate or 
calcium (Table 2), in agreement with the lack of effect on plasma PTH levels (Figure 7). The 
CKD mice were hyperphosphatemic (Table 2), which occurs somewhat earlier than the onset 
of hyperphosphatemia in human stage 4 CKD. Plasma FGF-23 levels were stimulated by 
CKD and were further increased in the RAP-011-treated group (Figure 7).
Effects of activin A on ActRIIA levels and signaling during osteoclastogenesis
The dramatic effects of the ActRIIA ligand trap on bone turnover in the CKD mice naturally 
raised the question of the state of ActRIIA signaling in skeletal cells of the CKD mice and 
the nature of the ligand whose effects were affected by the trap. We recently reported that 
CKD increases circulating levels of activin A while not affecting follistatin or follistatin-like 
3 levels.16 We showed that the CKD mice harbor decreased levels of ActRIIA in the aorta 
and consequent decreased vascular ActRIIA signaling.16 Interestingly, kidney ActRIIA 
levels were not affected and renal ActRIIA signaling was increased in CKD.16 The ligand 
that most likely produced these effects was activin A produced by renal interstitial cells. 
Because bone-remodeling cycles begin with osteoclast stimulation, we studied the effects of 
activin A on osteoclastogenesis in vitro. Using bone marrow mononuclear cells (BMMCs), 
we demonstrated that activin A stimulates RANK ligand (RANKL)-induced 
osteoclastogenesis.33 Treatment of BMMCs with the receptor activator of nuclear factor-κB 
ligand (RANKL) is a standard technique of osteoclast production in vitro. As shown in 
Figure 8, activin A stimulation of BMMCs from WT mice enhanced RANKL-stimulated 
osteoclastogenesis, as shown by the levels of markers of mature or activated osteoclasts, 
nuclear factor of activated T cells c1 (NFATc1, an osteoclast transcription factor), cathepsin 
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K, and integrin subunit β3 at day 4 of BMMC stimulation with RANKL. d The mechanism 
of activin A effects on osteoclastogenesis are unknown. In Figure 9, using c-fos and p-Smad 
2 antibodies in chromatin immunoprecipitation assays), we show that c-fos forms a complex 
with the NFATc1 promoter during RANKL stimulation, but during activin A plus RANKL, 
both stimulated p-Smad2 and c-fos associated with the NFATc1 promoter forming a 
synergistic complex on NFATc1 (Figure 9), in agreement with studies showing direct 
association with c-Fos and p-Smad2.34
DISCUSSION
Our data demonstrate that CKD, with a GFR reduction of 70% in a diet-induced diabetic 
mouse model, is associated with a transition in skeletal remodeling from a low-turnover to a 
higher turnover state with increases in osteoclast and osteoblast number/surface in the 
presence of elevated PTH. The mechanical effect of this change on remodeling was an 
increase in compliance without a loss of strength. Treatment with an ActRIIA ligand trap 
reversed the transition toward higher turnover remodeling and increased trabecular and 
cortical bone volume without affecting PTH levels. RAP-011 had no effect on bone 
mechanical properties, but the trend toward an increase in compliance (without loss of 
strength) suggested a mechanism of action distinct from the mechanism by which CKD 
induced turnover may have affected bone mechanical properties. Although our data do not 
prove the identity of the ligand responsible for the effects of the ActRIIA ligand trap, the 
primary ActRIIA ligand, activin A, is a lead candidate. For example, circulating activin A 
levels were increased in CKD.16 Here, in in vitro studies, activin A enhanced RANKL-
stimulated osteoclastogenesis in bone marrow mononuclear cells, in agreement with 
previous studies,33,35 through p-Smad2 association with c-Fos on the NFATcl promoter. This 
finding is in agreement with recent studies of Omata et al.34
Our results are also supported by previous studies36 in which Smad2 activation was shown 
to stimulate bone remodeling in CKD independent of PTH. Liu et al.36 published results 
differ from ours in that the pathway to Smad2 activation was through the TGF-β type 2 
receptor activated by TGF-β and not through ActRIIA, as in our results. However, despite 
the difference in the mechanism of Smad2 activation, our results are in line with those of Liu 
et al.36 regarding the downstream effects of Smad2 inhibition—that of increased cortical and 
trabecular bone volume due to decreased osteoclast-mediated bone resorption and 
remodeling. The decrease in osteoclastogenesis and remodeling stimulated by RAP-011 
returned osteoblast number to the levels in sham mice and inhibited BFRs. However, bone 
formation per osteoblast was increased by RAP-011, reversing the CKD-induced inhibition. 
This may be due to decreased efficiency of the proliferating osteoblasts stimulated by CKD 
compatible with effects of the TGF-β family, including ActRIIA signaling, to stimulate 
osteoblast proliferation but restrict osteoblast maturation.37
Studies by Sabbagh et al.11 demonstrated repression of osteocytic Wnt/β-catenin signaling 
early in CKD and demonstrated an association with increased osteoclast activity 
independent of PTH. They attributed the decrease in bone formation produced by an 
antibody to TGF-β to inhibition of TGF-β receptor signaling in osteoblasts.36 By 
immunohistochemistry, they localized p-Smad2/3 to osteoblasts and bone marrow, but in our 
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studies of BMMC differentiation to osteoclasts, p-Smad2 was clearly present in osteoclasts. 
It is unclear whether the increase in TGF-β and TGF-βR1 shown by Sabbagh et al. were 
directly associated with the p-Smad2/3 immunohistochemistry results. Our results have a 
clear focus on the osteoclast because the stimulation of bone formation produced by 
RAP-011 in studies of nondiabetic chow-fed mice38 were blocked in our ldlr−/− high fat-fed 
mice.
The fact that early CKD causes a renal osteodystrophy was also studied in a rodent model by 
Moe et al.39 The authors used a polycystic kidney disease model in rats and demonstrated 
that at a 50% reduction in GFR in a slowly evolving kidney disease, there is a stimulation of 
osteoclastogenesis and bone turnover that produced mechanical weakening of long bones. 
Our results extend these studies by showing that factors in addition to PTH contribute to the 
stimulation of osteoclastogenesis and bone turnover in early CKD. The studies by Moe et 
al., Sabbagh et al., and Liu et al. and our results are in agreement that CKD with GFR 
reductions >50% causes a stimulation in bone remodeling through activating 
osteoclastogenesis, an effect mediated through Smad 2 activation, but attributed in the past 
to PTH. This apparent contradiction may be related to the interaction of the PTH receptor I 
and TGF-β receptor II.40
Results of studies by Lotinun et al.41 and Pearsall et al.38 demonstrating that RAP-011, or its 
human equivalent ACE-011, stimulated bone formation in monkeys, murine models, and 
humans with osteoporosis, differ from our findings. However, it is likely that activin A 
signaling is affected by environmental differences induced by high fat feeding-induced 
diabetes producing resistance to ActRIIA inhibition by RAP-011 in stimulating bone 
formation. Recent studies also suggest that activin A stimulation of osteoclastogenesis in 
vitro is mediated through stromal cells in the isolated bone marrow mononuclear cell 
preparation.42 However, our data showing activin A stimulation of c-fos activation of 
NFATc1 through a cooperative c-fos-p-Smad2 complex is an osteoclast precursor cell-
specific function. The actions of activin A on osteoclastogenesis and osteoclast function 
require additional study.
A limitation of the study is the low-turnover osteodystrophy found in the sham animals due 
to a decreased osteoblastogenesis response to bone resorption secondary to adipogenesis, 
similar to hyperlipidemic human type 2 diabetes in humans. The specific relationship of our 
model to type 2 diabetes produces questions regarding application of the findings to 
nondiabetic renal osteodystrophy. Another limitation of our studies is the severe skeletal 
frailty produced in the sham animals by the genotype and high-fat feeding. This may have 
served to diminish the effects of CKD on skeletal frailty.
In conclusion, with the common clinical background of high fat feeding-induced diabetes 
and hyperlipidemia, CKD (70% reduction in GFR) stimulated transition of a low-turnover 
osteodystrophy toward a higher turnover state due to osteoclastogenesis stimulated by p-
Smad2, which was prevented by treatment with an ActRIIA ligand trap. The lead candidate 
ActRIIA ligand, activin A, may have been produced in the kidney as we have previously 
shown16 and affected bone remodeling from the circulation. These results support 
modulation of ActRIIA signaling as a new therapeutic target in CKD.
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METHODS
The studies reported here used methodology previously reported,9,16 and detailed methods 
are found in the Supplementary Material. Briefly, the animals used were those previously 
described, using animal protocols approved by the Washington University Animal Studies 
Committee.16 Four groups of male mice were used in this study (Supplementary Figure 1). 
The skeletons of the 22-week-old CKD mice reported by Agapova et al.16 were not 
analyzed, but readers should consider this study as a treatment, not a prevention, trial. In 
other words, the effects of CKD were allowed to develop from 14 to 22 weeks before 
institution of the vehicle or RAP-011 treatment. The mice reported here also differ from the 
Dkk1 study9 in that their CKD was worse (GFR reductions equivalent to those seen in 
human CKD stage 3 compared with GFR reductions in Fang et al.9 equivalent to human 
CKD stage 2), and euthanasia was at 28 weeks instead of 22 weeks as in Fang et al. In Fang 
et al., CKD did not increase osteoclast and osteoblast numbers, and the low-turnover 
osteodystrophy of the sham animals persisted after the induction of mild CKD. The ldlr–/– 
high fat-fed mice with CKD that received subcutaneous injections of RAP-011 (Celgene, 
Summit, NJ), 10 mg/kg, were treated twice a week beginning at 22 weeks until they were 
killed at 28 weeks (CKD R). Inulin clearances were performed at 26 weeks if mice were 
killed at 28 weeks, according to manufacturer instructions (BioPal Inc., Worcester, MA). 
Serum was analyzed on the day of blood draw for blood urea nitrogen, calcium, and 
phosphate by standard autoanalyzer laboratory methods performed by our animal facility. 
Plasma PTH and FGF-23 levels were determined by enzyme-linked immunosorbent assays. 
EDTA based platelet-poor plasma samples were made by 2-step centrifugation at 6000 rpm 
for 5 minutes and 14,000 rpm for 2 minutes (at 4 °C). Samples were stored at −20 °C or 
below until used. Plasma FGF-23 levels were measured using a mouse C-terminal kit 
(Immunotopics, San Clemente, CA) and intact PTH levels (ALPCO Diagnostic, Salem, 
NH). Enzyme-linked immunosorbent assay was performed according to the manufacturers’ 
recommendations. The absorbance was read at 450 nm using a microplate reader 
(VERSAmax Molecular Devices, Molecular Devices, LLC, Sunnyvale, CA).
Chromatin immunoprecipitation assays
The cells were treated with RANKL (100 ng/ml) with or without activin A (100 ng/ml) for 
24 hours. Chromatin immunoprecipitation assay was performed with the simple chromatin 
immunoprecipitation plus enzymatic chromatin IP kit (Cell Signaling, Danvers, MA) 
according to the manufacturer’s suggestions using antibodies against histone H3 (1:50 Cell 
Signaling), normal rabbit IgG (1:100 Cell Signaling), p-c-Fos (1:50 Cell Signaling), or p-
Smad2 (1:50 Cell signaling). The purified DNA was analyzed by polymerase chain reaction 
using primers that detect sequences containing the mouse NFATc1 promoter (forward: 5-
CCGGGACGCCCATGCAATCTGTTAGTAATT-3, and reverse: 5-
GCGGGTGCCCTGAGAAAGCTACTCTCCCTT-3). All primers were synthesized by 
Integrated DNA Technologies (Coralville, IA).
Statistics
One-way analysis of variance statistical analysis of the data was performed using SigmaPlot 
version 12.5 (Systat Software Inc., San Jose, CA), and the differences in the mean values 
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among the treatment groups were considered statistically significant at P < 0.05. The 
normality of the data was assessed by the Shapiro-Wilk normality test. The Holm-Sidak 
method was used for all pairwise multiple comparison procedures. All data are expressed as 
mean ± SE. The differences between groups in the mechanical bending data were assessed 
by post hoc Tukey tests. Data for all groups represent a number of 7 to 20.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effects of chronic kidney disease (CKD) and RAP-011 on osteoclasts and bone 
resorption
CKD stimulated osteoclast number (Oc.N.) per bone length (BL) and osteoclast surface per 
bone surface (Oc.S./BS) along with eroded surface per bone surface (ES/BS) in the distal 
femoral metaphysis. RAP-011 treatment reversed the effects of CKD. **P < 0.01 for 
comparisons between sham and chronic kidney disease mice treated with vehicle (CKD V) 
and between CKD V and CKD R. CKD R, CKD+RAP-011; WT, wild type.
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Figure 2. Osteoblasts and bone formation in the various groups of mice
The sham (ldlr−/− high-fat fed) mice had reduced osteoblast number, surfaces, and bone 
formation rate (BFR) in the distal femoral metaphysis. BFR per osteoblast (BFR/Ob) was 
decreased in the sham mice. Chronic kidney disease (CKD) stimulated osteoblast number 
(Ob.N.) per bone length (BL) and osteoblast surface per bone surface (Ob.S./BS). There was 
a trend of CKD to increase BFR/BS. BFR/Ob was decreased by CKD. RAP-011 treatment 
reversed the effects of CKD on osteoblast numbers and surface, decreased BFR/BS, and 
increased BFR/Ob. **P < 0.01 for comparisons between wild type (WT) and sham, between 
sham and chronic kidney disease mice treated with vehicle (CKD V), and between CKD V 
and CKD R. CKD R, CKD+RAP-011.
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Figure 3. Osteoid and mineralization in the various groups of mice
Osteoid volume (OV), osteoid surface (OS), and mineral apposition rate (MAR) were 
decreased in the sham (Ldlr−/− high-fat fed) mice. Chronic kidney disease (CKD) did not 
affect these parameters compared with sham mice. RAP-011 treatment decreased OV and 
OS compared with chronic kidney disease mice treated with vehicle (CKD V). **P < 0.01 
for comparisons between wild type (WT) and sham and between CKD V and CKD R. CKD 
R, CKD+RAP-011.
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Figure 4. Micro computed tomography analysis of trabecular bone in the distal femoral 
metaphysis
Chronic kidney disease (CKD) increased trabecular bone volume (BV/TV) and bone mineral 
density (BMD). RAP-011 treatment increased BV/TV and trabecular number (Tb.N) and 
decreased trabecular separation (Tb.Sp.). CKD R, CKD+RAP-011; CKD V, chronic kidney 
disease mice treated with vehicle; Tb.Th, trabecular bone thickness; WT, wild type. **P < 
0.01 for comparisons between sham and CKD R.
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Figure 5. Micro computed tomography analysis of cortical bone
Total and cortical bone area were decreased in the sham (ldlr−/− high-fat fed) mice. Chronic 
kidney disease increased total cortical area (Tt.Ar), decreased cortical bone area fraction 
(Ct.Ar/Tt.Ar) and decreased cortical bone thickness (Ct.Th). RAP-011 treatment increased 
cortical bone area (Ct.Ar) and cortical thickness (Ct.Th). CKD R, CKD+RAP-011; TMD, 
tissue mineral density; WT, wild type *P < 0.05 for comparisons between sham and CKD V 
and between CKD V, chronic kidney disease mice treated with vehicle (CKD V) and CKD 
R; **P < 0.01 for comparisons between WT and sham and between sham and CKD V; ***P 
< 0.001 for comparisons between sham and CKD R.
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Figure 6. Effects of chronic kidney disease (CKD) and RAP-011 on mechanical properties of 
femurs
At the tissue level, CKD resulted in increased toughness (through increased total strain) 
without a change in strength. There were no significant effects of RAP-011 on mechanical 
testing parameters compared with CKD. P < 0.026 for comparisons between sham and 
chronic kidney disease mice treated with vehicle (CKD V).
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Figure 7. Effects of chronic kidney disease (CKD) and RAP-011 on parathyroid hormone (PTH) 
and fibroblast growth factor 23 (FGF-23) levels of the various mouse groups
(a) CKD induced significant increases in PTH levels, which were not affected by treatment 
with RAP-011. (b) CKD induced significant increases in the FGF-23 levels, which were 
further increased in the RAP-011-treated mice. Data are mean ± SD. *P < 0.05 for 
comparisons between sham and chronic kidney disease mice treated with vehicle (CKD V), 
wild-type (WT) mice and CKD V, and CKD V and CKD R; **P < 0.01 for comparison 
between WT and CKD V. CKD R, CKD+RAP-011.
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Figure 8. Effects of activin A on osteoclastogenesis
Treatment of bone marrow mononuclear cells with RANK ligand (RANKL) for 4 days as 
described in Methods was used to induce differentiation to osteoclasts. Osteoclast 
production, which we have previously reported on,35 was marked by induction of the 
specific transcription factor nuclear factor of activated T cells c1 (NFATc1), and the 
osteoclast phenotype differentiation markers cathepsin K and integrin subunit β3. Treatment 
with activin A enhanced RANKL-stimulated osteoclastogenesis and induction of NFATc1, 
cathepsin K, and integrin β3. Activin A treatment did not affect levels of activin receptor 
type 2A (ActRIIA), and increased p-Smad2 associated with NFATc1, as shown in Figure 9. 
D, day; M-CSF, macrophage colony-stimulating factor.
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Figure 9. Mechanism of activin A stimulation of osteoclastogenesis
Chromatin immunoprecipitation (ChIP) with antibodies to histone H3 (positive control), p-
cFos, and p-Smad2 in bone marrow mononuclear cells revealed the nuclear factor of 
activated T cells c1 (NFATc1) promoter associated with p-cFos in RANK ligand (RANKL)-
treated cells.34 Treatment with RANKL plus activin A revealed both p-cFos and p-Smad2 
associated with the NFATcl promoter.
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Table 1
Effect of chronic kidney disease and RAP-011 on mineralizing surfaces
WT Sham = 16
CKD
V = 19
CKD
R = 20
Mineralizing surface [dLS + (sLS/2)]/BS-% 6.88 11.09a 7.34
Mean ± SE 0.68 1.42 0.98
BS, bone surface; CKD R, CKD+RAP-011; CKD V, CKD mice treated with vehicle; dLS, double-labeled surface; sLS/2, single-labeled surface; 
WT, wild type.
aP < 0.01 compared with sham.
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Table 2
Serum biochemical parameters in the various groups of animals
Parameter Wild type Sham CKD V CKD R
Mouse strain C57/BJ6 ldlr−/− ldlr−/− ldlr−/−
Diet Chow High fat High fat High fat
Surgery None Sham CKD CKD
Weeks postnatal 28 28 28 28
Treatment None None Vehicle RAP-011
No. 12 15 14 15
BUN (mg/dl) 24.0 ± 4.6 20.6 ± 3.7 37.7 ± 7.6a 36.5 ± 5.8a
Ca (mg/di) 8.3 ± 1.8 8.9 ± 0.9 9.4 ± 0.8 8.8 ± 0.3
Phosphorus (mg/di) 8.9 ± 0.2 7.9 ± 2.3 11.0 ± 1.6a 11.8 ± 1.2a
BUN, blood urea nitrogen; Ca, calcium; CKD R, chronic kidney disease receptor; CKD V, chronic kidney disease mice treated with vehicle.
aP < 0.05, CKD V and CKD R compared with sham. Inulin clearances in the mice were reported in Agapova et al.16
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